• Muhammad Numair Younis Nuclear Medicine department INMOL
  • Humayun Bashir Nuclear Medicine Department, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore




Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: The early history. Thyroid 1997;7:163-76.

Sharp SE, Trout AT, Weiss BD, et al. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 2016;36:258-78.

Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016;43:1723-38.

Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med 2017;42:905-11.

Dorff TB, Agarwal N. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian J Androl 2018;20:215-20.

Lee DY, Li KC. Molecular theranostics: A primer for the imaging professional. AJR Am J Roentgenol 2011;197:318-24.

Oberg K. Molecular imaging radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012;2:448-58.

Kulkarni HR, Singh A, Baum RP. Advances in the diagnosis of neuroendocrine neoplasms. Semin Nucl Med 2016;46:395-404.

Kunikowska J, Pawlak D, Bąk MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with90Y/177 Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: A 10-year study. Ann Nucl Med 2017;31:347-56.

Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-35.

Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with177 Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018;36:2578-84.

Mittra ES. Neuroendocrine tumor therapy:177 Lu-DOTATATE. AJR Am J Roentgenol 2018;211:278-85.

Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 2013;40:800-16.

Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:471-95.

Hofman M, Violet J, Sandhu S, et al. High activity, pain reduction and low toxicity with lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Results of a phase II prospective trial. J Nucl Med 2018;59 Supplement 1:531.

Keek SA, Leijenaar RT, Jochems A, et al. A review on radiomics and the future of theranostics for patient selection in precision medicine. Br J Radiol 2018;91:20170926.

How to Cite
Younis MN, Bashir H. THERANOSTICS- NEUROENDOCRINE TUMOURS. J Cancer Allied Spec [Internet]. 2018Jul.1 [cited 2020Sep.21];4(2). Available from: